Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGLT2 Inhibitors, Ketogenesis, and Ketoacidosis
NCT05960656Phase 1Recruiting
- Sponsor
- UT Health San Antonio
- Start
- Oct 2023
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial in type 2 diabetes mellitus (T2DM) comparing Empagliflozin 25 mg/day with Placebo (2 arms). Primary endpoint: Endogenous Glucose Production at 300 minutes. Started Oct 2023; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05960656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05960656.